Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16282248rdf:typepubmed:Citationlld:pubmed
pubmed-article:16282248lifeskim:mentionsumls-concept:C0017416lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C0079083lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C1522690lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:16282248lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:16282248pubmed:issue1lld:pubmed
pubmed-article:16282248pubmed:dateCreated2005-12-19lld:pubmed
pubmed-article:16282248pubmed:abstractTextSingle-agent platinum and single-agent pegylated liposomal doxorubicin (PLD) are both effective in the treatment of gynecologic malignancies. Based on evidence that combination platinum-containing regimens offer superior efficacy versus single-agent regimens, we conducted this study to determine the maximum tolerated dose (MTD) of PLD in combination with carboplatin.lld:pubmed
pubmed-article:16282248pubmed:languageenglld:pubmed
pubmed-article:16282248pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16282248pubmed:citationSubsetIMlld:pubmed
pubmed-article:16282248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16282248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16282248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16282248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16282248pubmed:statusMEDLINElld:pubmed
pubmed-article:16282248pubmed:monthJanlld:pubmed
pubmed-article:16282248pubmed:issn0923-7534lld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:SchmalfeldtBBlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:MeierWWlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:PfistererJJlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:RichterBBlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:BurgesAAlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:JackischCClld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:du BoisAAlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:KimmigRRlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:ElseaVVlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:StaehleAAlld:pubmed
pubmed-article:16282248pubmed:authorpubmed-author:Arbeitsgemein...lld:pubmed
pubmed-article:16282248pubmed:issnTypePrintlld:pubmed
pubmed-article:16282248pubmed:volume17lld:pubmed
pubmed-article:16282248pubmed:ownerNLMlld:pubmed
pubmed-article:16282248pubmed:authorsCompleteYlld:pubmed
pubmed-article:16282248pubmed:pagination93-6lld:pubmed
pubmed-article:16282248pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:meshHeadingpubmed-meshheading:16282248...lld:pubmed
pubmed-article:16282248pubmed:year2006lld:pubmed
pubmed-article:16282248pubmed:articleTitlePegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).lld:pubmed
pubmed-article:16282248pubmed:affiliationHSK, Dr Horst Schmidt Klinik, Department of Gynecology & Gynecologic Oncology, Wiesbaden, Germany. dubois.hsk-wiesbaden@uumail.delld:pubmed
pubmed-article:16282248pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16282248pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16282248pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:16282248pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
pubmed-article:16282248pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16282248lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16282248lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16282248lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16282248lld:pubmed